Research programme: hepatitis C virus inhibitors - Myriad Pharmaceuticals
Alternative Names: MPYS 188Latest Information Update: 20 Feb 2009
At a glance
- Originator Myriad Pharmaceuticals
- Class
- Mechanism of Action Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 20 Feb 2009 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 24 Apr 2006 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
- 13 Jul 2004 This programme is still in active development